Ideally Suited for Satellite and Independent
Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and
Data Commutability with Extensive Chemistry and Immunoassay Assay
Menu
The New DxC 500i Analyzer Incorporates
Recently Introduced DxC 500 AU Chemistry Analyzer Technology
with Six Sigma Performance
BREA,
Calif., July 9, 2024 /PRNewswire/ -- Beckman
Coulter Diagnostics, a clinical diagnostics leader, today
introduces the new DxC 500i Clinical Analyzer*, an integrated
clinical chemistry and immunoassay analyzer. As healthcare systems
around the world strategically adopt networked laboratory
operational models for better efficiency and patient access,
Beckman Coulter continues to introduce new innovations to address
the needs of the entire network with specific solutions for
satellite or independent laboratories, as well as core
laboratories. Utilizing Beckman Coulter's common reagents and
consumables across its scalable clinical chemistry and immunoassay
portfolio, the DxC 500i Analyzer enables commutable patient
results, offering hospitals and healthcare networks strategic
benefits in patient care and inventory management.
"The development of the DxC 500i Analyzer is yet another example
of how Beckman Coulter is investing in the needs of a broad range
of laboratories across healthcare systems," said Kathleen Orland, Senior Vice President, Business
Unit, General Manager, Chemistry and Immunoassay for Beckman
Coulter Diagnostics. "The DxC 500i Clinical Analyzer powers both
clinical chemistry and immunoassay testing in one space-saving
package. With steadfast performance, practical simplicity, and
trusted clinical quality, this analyzer meets the specific demands
of the low-volume laboratory customer, standalone laboratories and
community hospitals."
The DxC 500i Clinical Analyzer features FlexMode operations,
prioritizing immunoassay and chemistry testing according to each
sample's urgency. The new dynamic sample handler manages repeats
and re-runs without operator intervention and pulls in a new sample
rack as soon as the previous rack is offloaded, optimizing rapid
throughput in a compact footprint. Of equal importance, the DxC
500i's intuitive interface supports even the newest users through
proactive task indicators, step-by-step instructions and simplified
staff onboarding and training.
In January, Beckman Coulter unveiled the DxC 500 AU Chemistry
Analyzer, an automated clinical chemistry analyzer with onboard
guided workflows, more than 120 assays, and standardized reagents
for use across healthcare networks. The DxC 500i analyzer
incorporates the DxC 500 AU technology within its clinical
chemistry capabilities, including its Six Sigma performance.
The DxC 500i Clinical Analyzer is currently available in
countries accepting CE mark.
Pending submission and clearance by the United States Food and
Drug Administration, the analyzer is not yet available for in vitro
diagnostic use in the U.S. Not all products are available in all
countries. Product availability and regulatory status depends
on country registration per applicable regulations.
Follow and connect with Beckman Coulter Diagnostics
via LinkedIn, X, and Facebook.
About Beckman Coulter Diagnostics
A global leader in advanced diagnostics, Beckman Coulter has
challenged convention to elevate the diagnostic laboratory's role
in improving patient health for more than 80 years. Our mission is
to Relentlessly Reimagine Healthcare, One Diagnosis at a
Time – and we do this by applying the power of science,
technology and the passion and creativity of our teams. Our
diagnostic solutions are used in complex clinical testing, and are
found in hospitals, reference laboratories and physician office
settings around the globe. We exist to deliver smarter, faster
diagnostic solutions that move the needle forward from what's now
to what's next. We seek to accelerate care with an extensive
clinical menu, scalable lab automation technologies, insightful
clinical informatics, and optimize lab performance services.
Headquartered in Brea, Calif.,
with more than 11,000 global team members, Beckman Coulter
Diagnostics is proud to be part of Danaher (NYSE: DHR).
Danaher is a global science and technology leader. Together we
combine our capabilities to accelerate the real-life impact of
tomorrow's science and technology to improve human health.
© 2024 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo, and the Beckman Coulter product and service
marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc. in the United
States and other countries. All other trademarks are the
property of their respective owners. 2024-13120
View original content to download
multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-introduces-new-integrated-chemistry-and-immunoassay-analyzer-302191394.html
SOURCE Beckman Coulter Diagnostics